Deep Vein Thrombosis
📧 Sign up to get email alerts when something new happens for Deep Vein Thrombosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-12-29FDA Approved: HEPARIN SODIUM — Original Application (BE Pharmaceuticals Inc.)
The FDA approved BE Pharmaceuticals Inc.'s original application for Heparin Sodium (a generic anticoagulant). It is used to prevent and trea…
-
FDA approval · 2020-08-25FDA Approved: ARIXTRA — Supplemental Application (Mylan Institutional LLC)
FDA approves a supplemental application for ARIXTRA (fondaparinux sodium) submitted by Mylan Institutional LLC.
-
FDA approval · 2020-07-15FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' generic heparin sodium (Original Application) as an injectable anticoagulant. It covers the same indi…
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis [Phase 3]
Phase 3 trial update evaluating the efficacy of apixaban in patients with malignancy-associated deep vein thrombosis.
-
FDA approval · 2020-06-18FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for ENOXAPARIN SODIUM by Sandoz Inc, signaling an approved change to the product's status under the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-05-06FDA Approved: DABIGATRAN ETEXILATE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original application for a generic dabigatran etexilate (ANDA 207961) from XLCare Pharmaceuticals, confirming the generic’s…
-
FDA approval · 2020-04-02FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original application for a generic heparin sodium product.
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: Calf Deep Vein Thrombosis Treatment Trial [Phase 4]
A Phase 4 clinical trial on treatment for deep vein thrombosis was terminated; results posted in 2020.
-
FDA approval · 2020-03-19FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Italfarmaco SpA)
FDA approved a supplemental application for ENOXAPARIN SODIUM submitted by Italfarmaco SpA.
-
CLINICAL_TRIALS trial_result · 2020-03-11Clinical Trial Update: Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
A completed clinical trial assessing the implementation of a national point-of-care ultrasound training program and its effects on various a…
-
FDA approval · 2020-03-11FDA Approved: DABIGATRAN ETEXILATE — Original Application (Major Pharmaceuticals)
FDA approved the original application for dabigatran etexilate from Major Pharmaceuticals, approving a generic version of the anticoagulant …
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System [Phase 4]
Phase 4 trial update on treating chronic deep vein thrombosis and post-thrombotic syndrome using the EkoSonic Endovascular System; results p…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis [Phase 4]
Phase 4 trial assessing rivaroxaban with diosmin for long-term treatment of deep vein thrombosis and postthrombotic syndrome; study complete…
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban [Phase 4]
A phase 4 trial comparing enoxaparin to rivaroxaban for preventing deep vein thrombosis is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: Education Bundle to Decrease Patient Refusal of VTE Prophylaxis [NA]
A completed clinical trial evaluating an education bundle to reduce patient refusal of venous thromboembolism prophylaxis.
-
CLINICAL_TRIALS trial_result · 2019-12-24Clinical Trial Update: Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism [Phase 3]
Phase 3 trial comparing apixaban to dalteparin for reducing blood clots in cancer-associated venous thromboembolism has completed with resul…
-
FDA approval · 2019-11-20FDA Approved: HEPARIN SODIUM — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Heparin Sodium from Gland Pharma Limited (ANDA205323). This action confirms continued availabili…
-
FDA approval · 2019-10-31FDA Approved: WARFARIN SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Warfarin Sodium (Warfarin) from Amneal Pharmaceuticals LLC.
-
FDA approval · 2019-09-26FDA Approved: WARFARIN SODIUM — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Warfarin Sodium by Exelan Pharmaceuticals. This action updates the regulatory status of this…
-
FDA approval · 2019-09-20FDA Approved: JANTOVEN — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for JANTOVEN (warfarin sodium) submitted by Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff [NA]
Clinical trial update for the Recovery Force DVT II Cuff shows a completed study with results posted in 2019.
-
FDA approval · 2019-08-23FDA Approved: XARELTO — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for XARELTO (rivaroxaban) filed by Janssen Pharmaceuticals, resulting in labeling changes to the pro…
-
FDA approval · 2019-05-28FDA Approved: HEPARIN SODIUM — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals Inc.'s Heparin Sodium as an Original Application (ANDA 211007), making a generic injectable anticoagul…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism [Phase 3]
A Phase 3 trial evaluating dabigatran etexilate as the primary treatment for malignancy-associated venous thromboembolism is underway, with …
-
FDA approval · 2019-03-14FDA Approved: ENOXAPARIN SODIUM — Original Application (Amphastar Pharmaceuticals, Inc.)
FDA approved Amphastar Pharmaceuticals' generic enoxaparin sodium injection (ANDA 208600). This marks approval of a generic version of enoxa…